Lipid-based Nanoparticles for the Pharmaceutical Industry: Pre-clinical and Clinical Advancements

Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the R&D Advances for Lipid Nanoparticles in the Pharmaceutical Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Research Methodology

Lipid-Based Nanoparticles: Overview and Significance

LNPs Are Better Suited than Liposomes for Nucleic Acid Delivery

Next-generation Lipid-based Nanocarriers Display Promising Attributes in Encapsulation and Large-scale Production

Second-generation LNPs Offer Better Design Flexibility and Improved Stability

Second-generation LNPs Offer Better Design Flexibility and Improved Stability (continued)

First-generation Lipid-based Nanoparticles Are Used Widely in the Cosmetics, Food & Beverage, and Nutraceuticals Industries

Research Scope

Segmentation

Growth Drivers

Growth Restraints

LNPs Constitute a Mix of Lipids and Stabilizers

Approved LNP Formulations Encapsulate Diverse Cargo of Different Chemical & Physical Properties

Mixing Ratio of Lipids and Aqueous Phase Critically Determine the Size of LNPs and their Entrapment Efficiency

High Pressure Homogenization Is the Preferred Choice for Large-scale Manufacturing of LNPs

Microfluidics and Super Critical Fluid Technology Offer Improved Control over Particle Size and Distribution

Formulation Techniques Play a Critical Role in Determining Size, Solvent Residue, and Distribution

Active and Passive Targeting of LNPs Exhibit Improved Cellular Penetration of Therapeutics with Minimal Systemic Toxicity

Rational Design of Lipids for Improved In Vivo Stability of mRNA Vaccines and Therapeutics Drives Commercialization

Lipid-based Nanocarriers Increasingly Used in the Treatment of Various Diseases

LNPs Conjugated with Antibody/Ligands Exhibit High Specificity for Cancer Targeting

Design and Use of New Phospholipid Combinations, Linkers, and Cholesterol Alternatives Improve In Vivo Stability, Safety, and Transfection of LNPs

Lipid and Polymer Hybrid LNPs offer Synergistic Benefits with Improved Stability and Targeting

In-line Detection and Tracking of LNPs Formulation Minimizes Production Time and Enables Process Feedback Control

Intramuscular and Intravenous Routes of Delivery Are Most Preferred for LNP-based Therapeutics

Surface Modification of LNPs and Lyophilization of Lipids and Cargo Exhibit Improved Stability for Long-term Storage

North America Secures High Funding for Commercial Development of LNP-based Therapeutics

Private Funding Focuses on Improved LNP Formulations for Vaccines and Immunotherapeutics

Entry of Thermostable and Targeted LNPs-based Therapeutics into Clinical Trials

Pharmaceutical Companies Innovate in the Stability, Biodegradation, Formulation, and Cost-Effectiveness of LNPs

Lipid Manufacturers Collaborate with API Developers to Leverage LNP-based Therapeutics

Therapeutic and Vaccine Formulations Using LNPs Are in Different Phases of Clinical Trial

North America Holds Highest Share of Patent Filings for LNPs

Leading LNPs and mRNA Players Battle on Patent Infringement

Growth Opportunity 1: In-silico and AI-based Lipid Composition Prediction

Growth Opportunity 1: In-silico and AI-based Lipid Composition Prediction (continued)

Growth Opportunity 2: Formulation of Stable LNPs with Improved Functionality

Growth Opportunity 2: Formulation of Stable LNPs with Improved Functionality (continued)

Growth Opportunity 3: Automated and Microfluidics-based LNP Manufacturing Platform

Growth Opportunity 3: Automated and Microfluidics-based LNP Manufacturing Platform (continued)

Growth Opportunity 4: Directed Development of LNPs for Tissue-targeted Delivery

Growth Opportunity 4: Directed Development of LNPs for Tissue-targeted Delivery (continued)

Technology Readiness Levels (TRL): Explanation

Your Next Steps

Why Frost, Why Now?

Legal Disclaimer